Highlights

  • H1 2026 revenue of US$477 million, up 22% year-on-year; full-year 2026 revenue to exceed US$1 billion
  • Precision Medicine gross margin of 65%; Group gross margin improved to 55%
  • Strategic collaboration with Regeneron for next-generation radiopharmaceutical therapies
  • CMS initiates NDA review for glioma imaging candidate Pixclara; ProstACT Global Part 2 enrollment progressing

Telix Pharmaceuticals Limited (ASX:TLX, NASDAQ:TLX), trading at A$16.26 as at 30 October 2026, has emerged as one of Australia's most commercially successful biopharmaceutical companies after reporting first-half 2026 group revenue of US$477 million – a 22% increase on the prior year period – and upgrading full-year guidance to revenue exceeding US$1 billion, a milestone that would establish Telix as a genuinely global radiopharmaceutical company with substantial commercial-stage and pipeline assets.

H1 2026 Financial Results

Telix's H1 2026 results, announced on 20 August 2026, demonstrated the sustained commercial momentum of its two-product precision medicine strategy. Group revenue of US$477 million for the six months ended 30 June 2026 was underpinned by the Precision Medicine segment, which delivered revenue growth of 27% year-on-year driven by volume growth in both Illuccix (PSMA PET imaging) and Gozellix. Group gross margin improved to 55% (up 2% year-on-year) and Precision Medicine gross margin was 65%. Adjusted EBITDA of US$52 million was up 146% year-on-year, with the result including a US$40 million initial non-refundable payment received from Regeneron under a new strategic collaboration. Profit after tax was US$38 million.

Regeneron Collaboration: Next-Generation Radiopharmaceutical Therapies

One of the most strategically significant events for Telix in 2026 was the announcement of a strategic collaboration with Regeneron Pharmaceuticals to jointly develop and commercialise next-generation radiopharmaceutical therapies. The collaboration, announced in April 2026, combines Telix's radiopharmaceutical manufacturing and delivery expertise with Regeneron's antibody biology capabilities and clinical development resources. Regeneron's initial non-refundable payment of US$40 million was received during H1 2026. The collaboration is expected to generate additional milestone and royalty payments over time as the programs advance. Management described the Regeneron partnership as a validation of Telix's global positioning in radiopharmaceuticals.

Pipeline: Multiple Late-Stage Regulatory Milestones

Beyond its commercial imaging products, Telix has built a late-stage pipeline across multiple cancer indications. Pixclara (TLX101-Px), the Company's glioma brain tumour imaging agent, was granted a PDUFA goal date of 11 September 2026 by the FDA. Pixlumi's Marketing Authorization Application was validated and accepted for review by the European Medicines Agency. ProstACT Global, Telix's lead prostate cancer therapeutic candidate (TLX591-Tx), completed Part 1 lead-in with no new safety signals, and the FDA confirmed Part 1 data supports progression to Part 2 US enrollment. TLX250-Tx dosed its first patient in the LUTEON pivotal trial for kidney cancer therapy.

Manufacturing and Global Expansion

Telix Manufacturing Solutions (TMS) reported total segment revenue of US$146 million in H1 2026, operating production facilities in Sacramento (US), Seneffe (Belgium), North Melbourne (Australia), and Yokohama (Japan). Telix completed a US$600 million convertible bond issuance in April 2026 to refinance existing convertible bonds, extending the maturity of the Company's debt to 2031 and strengthening the balance sheet to support continued commercial and pipeline investment.